Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;45(8):1360-2.
doi: 10.1038/bmt.2009.338. Epub 2009 Dec 7.

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma

S S Tykodi, L N Voong, E H Warren

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma

S S Tykodi et al. Bone Marrow Transplant. 2010 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

None.

Figures

Figure 1
Figure 1. Rapamycin Effects on RCC Tumor Cell Growth in Vitro
RCC tumor cell lines were cultured with or without rapamycin for 6 days. The number of viable cells identified by trypan-blue exclusion was normalized to untreated cultures. Similar data was obtained with 11 additional RCC tumor lines (not shown)
Figure 2
Figure 2. Rapamycin Effects on CTL Recognition of RCC Tumor Cells in Vitro
Patient (P) or donor (D)-derived LCL lines and four HLA-A2-expressing RCC target lines and were chromium-labeled and used as targets in a 4-hour cytotoxicity assay with CTL Clone 9 specific for HA-1 at an effector:target ratio of 10:1. RCC targets were cultured with (filled bars) or without (open bars) addition of rapamycin at 10 ng/ml for four days. Alleles of the HMHA1-1 gene that encodes HA-1 were previously reported and are indicated for each target line. The antigenic allele encodes for histidine (H) at position 3 of the T cell epitope whereas the alternate allele encodes arginine (R).
See this image and copyright information in PMC

Comment in

References

    1. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol. 2006;17:1134–40. - PubMed
    1. Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008;118:1099–109. - PMC - PubMed
    1. Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant. 2009;44:237–42. - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. - PubMed
    1. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11. - PubMed

Publication types

MeSH terms

Substances